Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Santhera Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3RD ANNUAL ARTIFICIAL INTELLIGENCE

              Participation Not Confirmed

              Update your events

              Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

              Contact the Supplier

              Lead Product(s): Lonodelestat

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: CSHL

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 27, 2020

              Details:

              Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

              Light Chain Bioscience

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3RD ANNUAL ARTIFICIAL INTELLIGENCE

              Participation Not Confirmed

              Update your events

              Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

              Contact the Supplier

              Lead Product(s): NI-0101

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Edesa Biotech

              Deal Size: $372.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 20, 2020

              Details:

              The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

              PharmaCompass__DigitalAd